Home > Insider Trading > Filing (0000899243-17-018092)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1420565	Aileron Therapeutics Inc	ALRN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1552293	Edward S. Torres	C/O Lilly Ventures 115 West Washington Street, Suite 1680-S Indianapolis IN 46204	No	No	No	Yes
1575852	Lilly Ventures Fund I Llc	115 West Washington Street Suite 1680-South Indianopolis IN 46204	No	No	No	Yes
1602732	Edward Steven Hall	C/O Lilly Ventures 115 West Washington Street, Suite 1680-S Indianapolis IN 46204	No	No	No	Yes
1681884	Lv Management Group, Llc	115 West Washington Street Suite 1680-South Indianapolis IN 46204	No	No	No	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-07-05	844,987	$0.00	844,987	No	4	C	Indirect	By Fund
Common Stock	Acquisiton	2017-07-05	250,000	$15.00	1,094,987	No	4	P	Indirect	By Fund

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Fund
No	4	P	Indirect	By Fund

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D Preferred Stock	Disposition	2017-07-05	3,390,885	$0.00	341,238	$0.00
Common Stock	Series E-2 Preferred Stock	Disposition	2017-07-05	1,907,373	$0.00	191,946	$0.00
Common Stock	Series E-3 Preferred Stock	Disposition	2017-07-05	1,654,411	$0.00	166,489	$0.00
Common Stock	Series F Preferred Stock	Disposition	2017-07-05	1,443,972	$0.00	145,312	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which consists of Ed Torres, Dr. Steve Hall and Armen B. Shanafelt. Each of the individuals and entities listed above expressly disclaims beneficial ownership of the shares held by LVFI, except to the extent of his or its respective pecuniary interest therein. Dr. Shanafelt is a director of the Issuer and, accordingly, files separate Section 16 reports.